Pages that link to "Q38070443"

The following pages link to A pooled analysis of 2618 patients treated with trastuzumab beyond progression for advanced breast cancer (Q38070443):

Displaying 17 items.

• Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway (Q26799382) (← links)
• The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer (Q33573092) (← links)
• Safety and efficacy evaluation of pertuzumab in patients with solid tumors (Q33714388) (← links)
• Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway (Q33917551) (← links)
• Current Approaches and Emerging Directions in HER2-resistant Breast Cancer (Q34016480) (← links)
• HER2-positive, trastuzumab-resistant metastatic esophageal cancer presenting with brain metastasis after durable response to dual HER2 blockade: a case report (Q34484252) (← links)
• Effectiveness of trastuzumab in first-line HER2+ metastatic breast cancer after failure in adjuvant setting: a controlled cohort study (Q34641036) (← links)
• Multiple gene aberrations and breast cancer: lessons from super-responders (Q35645466) (← links)
• Drug rechallenge and treatment beyond progression--implications for drug resistance. (Q35967416) (← links)
• Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience (Q37100311) (← links)
• Continuation of trastuzumab beyond disease progression in HER2-positive metastatic gastric cancer: the MD Anderson experience. (Q37131686) (← links)
• A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer (Q37534928) (← links)
• Evaluation of Left Ventricular Ejection Fractions in Breast Cancer Patients Undergoing Long-Term Trastuzumab Treatment. (Q37543832) (← links)
• Trastuzumab beyond progression for HER2 positive metastatic breast cancer: progression-free survival on first-line therapy predicts overall survival impact (Q38225376) (← links)
• Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance (Q89683058) (← links)
• Survival of Hepatocellular Carcinoma Patients Treated with Sorafenib beyond Progression (Q90685833) (← links)
• Trastuzumab treatment after progression in HER2-positive metastatic breast cancer following relapse of trastuzumab-based regimens: a meta-analysis (Q92861867) (← links)